{"count": 5, "results": [{"_id": "40033492", "pmid": 40033492, "title": "EXPRESS: Metformin; Its Salutary Effects Beyond Diabetes Mellitus.", "journal": "J Investig Med", "authors": ["Sawalha K", "Gautam N", "Sivakumar K", "Paydak H", "Mehta J"], "date": "2025-03-03T00:00:00Z", "doi": "10.1177/10815589251327511", "meta_date_publication": "2025 Mar 3", "meta_volume": "", "meta_issue": "", "meta_pages": "10815589251327511", "score": 50259.15, "text_hl": "Studies have shown its use is associated with reduction in major cardiovascular events (MACE) in @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ such as hospitalization for acute @DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@myocardial infarction@@@, @DISEASE_Stroke @DISEASE_MESH:D020521 @@@stroke@@@, @<m>DISEASE_Ischemic_Attack_Transient</m> @DISEASE_MESH:D002546 @@@transient ischemic attack@@@, or @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@cardiovascular death@@@. [1-6] There is also a suggestion that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may have effects beyond those relating to lowering of @CHEMICAL_Blood_Glucose @CHEMICAL_MESH:D001786 @@@blood sugar@@@. ", "citations": {"NLM": "Sawalha K, Gautam N, Sivakumar K, Paydak H, Mehta J. EXPRESS: Metformin; Its Salutary Effects Beyond Diabetes Mellitus. J Investig Med. 2025 Mar 3;():10815589251327511. PMID: 40033492", "BibTeX": "@article{40033492, title={EXPRESS: Metformin; Its Salutary Effects Beyond Diabetes Mellitus.}, author={Sawalha K and Gautam N and Sivakumar K and Paydak H and Mehta J}, journal={J Investig Med}, pages={10815589251327511}}"}}, {"_id": "34531203", "pmid": 34531203, "pmcid": "PMC8449977", "title": "Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance", "journal": "BMJ Open", "authors": ["Osei E", "Zandbergen A", "Brouwers PJAM", "Mulder LJMM", "Koudstaal P", "Lingsma H", "Dippel DWJ", "den Hertog H"], "date": "2021-09-16T00:00:00Z", "doi": "10.1136/bmjopen-2020-046113", "meta_date_publication": "2021 Sep 16", "meta_volume": "11", "meta_issue": "9", "meta_pages": "e046113", "score": 50255.797, "text_hl": "Safety, feasibility and efficacy of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitagliptin@@@ in @SPECIES_9606 @@@patients@@@ with a @<m>DISEASE_Ischemic_Attack_Transient</m> @DISEASE_MESH:D002546 @@@TIA@@@ or minor @DISEASE_Cerebral_Infarction @DISEASE_MESH:D002544 @@@ischaemic stroke@@@ and @DISEASE_Glucose_Intolerance @DISEASE_MESH:D018149 @@@impaired glucose tolerance@@@", "citations": {"NLM": "Osei E, Zandbergen A, Brouwers PJAM, Mulder LJMM, Koudstaal P, Lingsma H, Dippel DWJ, den Hertog H. Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance BMJ Open. 2021 Sep 16;11(9):e046113. PMID: 34531203", "BibTeX": "@article{34531203, title={Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance}, author={Osei E and Zandbergen A and Brouwers PJAM and Mulder LJMM and Koudstaal P and Lingsma H and Dippel DWJ and den Hertog H}, journal={BMJ Open}, volume={11}, number={9}, pages={e046113}}"}}, {"_id": "26242578", "pmid": 26242578, "pmcid": "PMC4526305", "title": "Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial", "journal": "Trials", "authors": ["Osei E", "Fonville S", "Zandbergen AA", "Brouwers PJ", "Mulder LJ", "Lingsma HF", "Dippel DW", "Koudstaal PJ", "den Hertog HM"], "date": "2015-08-05T00:00:00Z", "doi": "10.1186/s13063-015-0882-z", "meta_date_publication": "2015 Aug 5", "meta_volume": "16", "meta_issue": "", "meta_pages": "332", "score": 50053.676, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitAgliptin@@@ in @SPECIES_9606 @@@patients@@@ with impAired @DISEASE_Glucose_Intolerance @DISEASE_MESH:D018149 @@@glucose tolerance@@@ and a recent @<m>DISEASE_Ischemic_Attack_Transient</m> @DISEASE_MESH:D002546 @@@TIA@@@ or minor @DISEASE_Cerebral_Infarction @DISEASE_MESH:D002544 @@@ischemic Stroke@@@ (MAAS): study protocol for a randomized controlled trial", "citations": {"NLM": "Osei E, Fonville S, Zandbergen AA, Brouwers PJ, Mulder LJ, Lingsma HF, Dippel DW, Koudstaal PJ, den Hertog HM. Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial Trials. 2015 Aug 5;16():332. PMID: 26242578", "BibTeX": "@article{26242578, title={Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial}, author={Osei E and Fonville S and Zandbergen AA and Brouwers PJ and Mulder LJ and Lingsma HF and Dippel DW and Koudstaal PJ and den Hertog HM}, journal={Trials}, volume={16}, pages={332}}"}}, {"_id": "23489282", "pmid": 23489282, "title": "Safety and feasibiLIty of Metformin in patients with Impaired glucose Tolerance and a recent TIA or minor ischemic stroke (LIMIT) trial - a multicenter, randomized, open-label phase II trial.", "journal": "Int J Stroke", "authors": ["den Hertog HM", "Vermeer SE", "Zandbergen AA", "Achterberg S", "Dippel DW", "Algra A", "Kappelle LJ", "Koudstaal PJ"], "date": "2015-01-01T00:00:00Z", "doi": "10.1111/ijs.12023", "meta_date_publication": "2015 Jan", "meta_volume": "10", "meta_issue": "1", "meta_pages": "105-9", "score": 50053.63, "text_hl": "@SPECIES_9606 @@@Patients@@@ with @<m>DISEASE_Ischemic_Attack_Transient</m> @DISEASE_MESH:D002546 @@@TIA@@@ or minor @DISEASE_Cerebral_Infarction @DISEASE_MESH:D002544 @@@ischemic stroke@@@ in the previous six months and @DISEASE_Glucose_Intolerance @DISEASE_MESH:D018149 @@@impaired glucose tolerance@@@ (2-hour post-load @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ levels of 7.8-11.0 mmol/l) were randomized to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, in a daily dose of 2 g, or no @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, for three months. ", "citations": {"NLM": "den Hertog HM, Vermeer SE, Zandbergen AA, Achterberg S, Dippel DW, Algra A, Kappelle LJ, Koudstaal PJ. Safety and feasibiLIty of Metformin in patients with Impaired glucose Tolerance and a recent TIA or minor ischemic stroke (LIMIT) trial - a multicenter, randomized, open-label phase II trial. Int J Stroke. 2015 Jan;10(1):105-9. PMID: 23489282", "BibTeX": "@article{23489282, title={Safety and feasibiLIty of Metformin in patients with Impaired glucose Tolerance and a recent TIA or minor ischemic stroke (LIMIT) trial - a multicenter, randomized, open-label phase II trial.}, author={den Hertog HM and Vermeer SE and Zandbergen AA and Achterberg S and Dippel DW and Algra A and Kappelle LJ and Koudstaal PJ}, journal={Int J Stroke}, volume={10}, number={1}, pages={105-9}}"}}, {"_id": "19591532", "pmid": 19591532, "title": "Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.", "journal": "Drug Saf", "authors": ["Hsiao FY", "Huang WF", "Wen YW", "Chen PF", "Kuo KN", "Tsai YW"], "date": "2009-01-01T00:00:00Z", "doi": "10.2165/00002018-200932080-00006", "meta_date_publication": "2009", "meta_volume": "32", "meta_issue": "8", "meta_pages": "675-90", "score": 50045.945, "text_hl": "RESULTS: @SPECIES_9606 @@@Patients@@@ receiving @CHEMICAL_Rosiglitazone @CHEMICAL_MESH:D000077154 @@@rosiglitazone@@@ monotherapy were at higher risk for any cardiovascular event (hazard ratio [HR] 1.89; 95% CI 1.57, 2.28), @DISEASE_Myocardial_Infarction @DISEASE_MESH:D009203 @@@myocardial infarction@@@ (HR 2.09; 95% CI 1.36, 3.24), @DISEASE_Angina_Pectoris @DISEASE_MESH:D000787 @@@angina pectoris@@@ (HR 1.79; 95% CI 1.39, 2.30) and @<m>DISEASE_Ischemic_Attack_Transient</m> @DISEASE_MESH:D002546 @@@transient ischaemic attack@@@ (HR 2.57; 95% CI 1.33, 4.96) than those receiving @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ monotherapy. ", "citations": {"NLM": "Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 2009;32(8):675-90. PMID: 19591532", "BibTeX": "@article{19591532, title={Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.}, author={Hsiao FY and Huang WF and Wen YW and Chen PF and Kuo KN and Tsai YW}, journal={Drug Saf}, volume={32}, number={8}, pages={675-90}}"}}]}